DROPLETS
A new analysis argues the slow pace of private fund exits stems not from a 'challenging environment' but from a discretionary choice by sponsors holding out for higher valuations to meet anchored IRR goals.
A new analysis challenges the widely held belief that a "challenging exit environment" is suppressing private fund M&A and IPO activity. The commentary argues that market indicators, from debt capital access to equity availability, show an exceptionally accommodative environment for financing transactions. Instead of external constraints, the lull in exits is attributed to a deliberate "timing preference" by fund sponsors.
This perspective is critical for sophisticated counsel and their clients because it reframes the deal slowdown as a discretionary choice, not a market necessity. Sponsors are reportedly holding onto assets because their anchored internal rate of return (IRR) expectations are difficult to achieve in the current interest-rate environment, creating a valuation disconnect with potential buyers. This insight helps clarify borrower motivations for lenders and highlights the strategic gamble sponsors are taking. The key development to watch is whether sponsors will reset their return targets or if rising asset values will eventually bridge the valuation gap.
A continuing resolution signed into law temporarily blocks the OMB's proposed rule that would make its grant guidance binding on all agencies and require political appointee review of discretionary awards.
President Trump signed the Continuing Appropriations and Extensions Act, 2027, a continuing resolution (CR) funding the U.S. government through December 11, 2026. A key provision within the CR blocks the Office of Management and Budget (OMB) from finalizing or implementing its May 2026 proposed rule on federal financial assistance. The proposed rule represents a significant shift in the administration of federal grants. It would transform the existing framework from nonbinding guidance into formally binding regulations applicable to all agencies. Crucially, the proposal would also require that discretionary awards receive a pre-issuance review from senior political appointees to ensure compliance with administration priorities and applicable law. This change could introduce a substantial new layer of political oversight into the grant-making process, affecting the many clients—from research institutions to non-profits—that depend on federal funding. The legislative block offers these stakeholders a temporary reprieve. The prohibition is tied to the CR's expiration date. Counsel for g
…
Investors and strategic partners are increasingly targeting the women's health sector, creating new opportunities but also demanding more rigorous clinical, regulatory, and transactional strategies.
The women's health sector is evolving from an underinvested niche into a commercially viable ecosystem, attracting heightened interest from investors, strategic partners, and pharmaceutical companies. This guide advises that stakeholders are now demanding more sophisticated and rigorous approaches to innovation, with a focus on closing historical data gaps and improving clinical evidence.
Sophisticated counsel should note that regulators and acquirers are increasing scrutiny on clinical trial diversity, the use of patient-centered endpoints, and the validity of data used for AI-enabled diagnostics. Companies developing drugs, devices, or digital health tools must navigate complex regulatory, privacy, and reimbursement landscapes to de-risk assets for financing or acquisition. For investors, due diligence must now more carefully assess the quality of women-specific clinical data, regulatory strategy, and data rights. Proactive legal strategy—addressing IP, contracts, and regulatory engagement early—is presented as critical for any company seeking to capitalize on the sector's growth.
The SEC's Division of Corporation Finance will no longer respond to any Rule 14a-8 no-action requests, leaving companies without an authoritative backstop for excluding shareholder proposals from proxy materials.
The SEC's Division of Corporation Finance announced it will no longer respond to any no-action requests under Exchange Act Rule 14a-8, effective immediately. This permanently expands a 2025 policy that had already sharply curtailed such responses. Companies have historically relied on these letters to gain the Division's informal agreement that a shareholder proposal could be legally excluded from proxy materials. Without this authoritative backstop, companies and their counsel bear the full risk of exclusion decisions, likely leading to more litigation from shareholder proponents challenging those determinations. Companies must still notify the SEC and proponents of any decision to exclude a proposal 80 days before filing definitive proxy materials, but counsel should now draft these notices for an audience of the proponent and, potentially, a court.
A new analysis argues the slow pace of private fund exits stems not from a 'challenging environment' but from a discretionary choice by sponsors holding out for higher valuations to meet anchored IRR goals.
A new analysis challenges the widely held belief that a "challenging exit environment" is suppressing private fund M&A and IPO activity. The commentary argues that market indicators, from debt capital access to equity availability, show an exceptionally accommodative environment for financing transactions. Instead of external constraints, the lull in exits is attributed to a deliberate "timing preference" by fund sponsors.
This perspective is critical for sophisticated counsel and their clients because it reframes the deal slowdown as a discretionary choice, not a market necessity. Sponsors are reportedly holding onto assets because their anchored internal rate of return (IRR) expectations are difficult to achieve in the current interest-rate environment, creating a valuation disconnect with potential buyers. This insight helps clarify borrower motivations for lenders and highlights the strategic gamble sponsors are taking. The key development to watch is whether sponsors will reset their return targets or if rising asset values will eventually bridge the valuation gap.
A new analysis argues the slow pace of private fund exits stems not from a 'challenging environment' but from a discretionary choice by sponsors holding out for higher valuations to meet anchored IRR goals.
A new analysis challenges the widely held belief that a "challenging exit environment" is suppressing private fund M&A and IPO activity. The commentary argues that market indicators, from debt capital access to equity availability, show an exceptionally accommodative environment for financing transactions. Instead of external constraints, the lull in exits is attributed to a deliberate "timing preference" by fund sponsors.
This perspective is critical for sophisticated counsel and their clients because it reframes the deal slowdown as a discretionary choice, not a market necessity. Sponsors are reportedly holding onto assets because their anchored internal rate of return (IRR) expectations are difficult to achieve in the current interest-rate environment, creating a valuation disconnect with potential buyers. This insight helps clarify borrower motivations for lenders and highlights the strategic gamble sponsors are taking. The key development to watch is whether sponsors will reset their return targets or if rising asset values will eventually bridge the valuation gap.
Investors and strategic partners are increasingly targeting the women's health sector, creating new opportunities but also demanding more rigorous clinical, regulatory, and transactional strategies.
The women's health sector is evolving from an underinvested niche into a commercially viable ecosystem, attracting heightened interest from investors, strategic partners, and pharmaceutical companies. This guide advises that stakeholders are now demanding more sophisticated and rigorous approaches to innovation, with a focus on closing historical data gaps and improving clinical evidence.
Sophisticated counsel should note that regulators and acquirers are increasing scrutiny on clinical trial diversity, the use of patient-centered endpoints, and the validity of data used for AI-enabled diagnostics. Companies developing drugs, devices, or digital health tools must navigate complex regulatory, privacy, and reimbursement landscapes to de-risk assets for financing or acquisition. For investors, due diligence must now more carefully assess the quality of women-specific clinical data, regulatory strategy, and data rights. Proactive legal strategy—addressing IP, contracts, and regulatory engagement early—is presented as critical for any company seeking to capitalize on the sector's growth.
A continuing resolution signed into law temporarily blocks the OMB's proposed rule that would make its grant guidance binding on all agencies and require political appointee review of discretionary awards.
President Trump signed the Continuing Appropriations and Extensions Act, 2027, a continuing resolution (CR) funding the U.S. government through December 11, 2026. A key provision within the CR blocks the Office of Management and Budget (OMB) from finalizing or implementing its May 2026 proposed rule on federal financial assistance. The proposed rule represents a significant shift in the administration of federal grants. It would transform the existing framework from nonbinding guidance into formally binding regulations applicable to all agencies. Crucially, the proposal would also require that discretionary awards receive a pre-issuance review from senior political appointees to ensure compliance with administration priorities and applicable law. This change could introduce a substantial new layer of political oversight into the grant-making process, affecting the many clients—from research institutions to non-profits—that depend on federal funding. The legislative block offers these stakeholders a temporary reprieve. The prohibition is tied to the CR's expiration date. Counsel for g
…
The SEC's Division of Corporation Finance will no longer respond to any Rule 14a-8 no-action requests, leaving companies without an authoritative backstop for excluding shareholder proposals from proxy materials.
The SEC's Division of Corporation Finance announced it will no longer respond to any no-action requests under Exchange Act Rule 14a-8, effective immediately. This permanently expands a 2025 policy that had already sharply curtailed such responses. Companies have historically relied on these letters to gain the Division's informal agreement that a shareholder proposal could be legally excluded from proxy materials. Without this authoritative backstop, companies and their counsel bear the full risk of exclusion decisions, likely leading to more litigation from shareholder proponents challenging those determinations. Companies must still notify the SEC and proponents of any decision to exclude a proposal 80 days before filing definitive proxy materials, but counsel should now draft these notices for an audience of the proponent and, potentially, a court.
Grade 3 — worth a glance, not the full analysis.
- SEC and CFTC Push Private Fund Reporting Compliance to July 2027
The SEC and CFTC adopted a joint final rule on August 31, 2026, extending the compliance date for 2024 Form PF amendments from October 1, 2026 to July 1, 2027, giving private fund advisers additional time amid ongoing regulatory revisions.
- state-attorneys-general-emerge-as-independent-antitrust-enforcers
Twelve state AGs successfully blocked the Paramount-Skydance merger without federal help, signaling a new era of dual-track antitrust enforcement that requires parties to navigate both federal and state regulatory pathways.
- Manufacturers' Guide to Tariff Volatility
A new checklist offers five key considerations for manufacturers to mitigate the impact of tariff changes on input costs, production, pricing, and supplier relationships.
- IEEPA tariff refunds for finally liquidated entries explained
Multinational importers should understand how to secure IEEPA tariff refunds for entries more than 80 days beyond liquidation, which fall outside CAPE Phase 1 processing.
- China's Anti-Cross-Border Corruption Law advances with first reading
China's draft Anti-Cross-Border Corruption Law, submitted for first reading on August 25, 2026, establishes sweeping extraterritorial reach and mandatory compliance obligations for companies with China operations.
- AI in Health Tech: A Guide for Investors and Operators
Lawyers advise healthcare investors and operators to look beyond AI hype and focus on integrated platforms, data governance, and demonstrable ROI when conducting diligence.
- Australia Russia Sanctions Tracker Summarizes Measures Post-2022
Lawyers advising clients on Australia-related Russia sanctions compliance can reference this updated tracker detailing asset freezes, travel bans, export/import restrictions, and 261 sanctioned vessels.
- Federal Court Vacates Education Dept Policy on Jay Treaty Student Aid
A U.S. district court ruled the Department of Education unlawfully required American Indian students born in Canada to obtain DHS immigration documents for federal student aid, finding the policy exceeded agency authority.
- Syndicated Loan Markets Showed Caution in H1 2026
Global syndicated loan issuance was marked by lender selectivity in the first half of 2026, with a strong preference for refinancing proven issuers over underwriting new risks amid macroeconomic uncertainty.
- AI in Marketing Poses Copyright and Advertising Risks
Brands using generative AI for marketing must ensure substantial human authorship to secure copyright and apply established advertising laws to avoid consumer deception.
- Texas AG Probes TriWest Over Alleged Wrongful Claim Denials
The Texas Attorney General is investigating federal contractor TriWest Healthcare Alliance for allegedly violating the state's Deceptive Trade Practices Act by improperly denying health claims for military members and veterans.
- Five Agencies Clarify SAR Confidentiality Rules for Bank-Customer Communications
FinCEN, Federal Reserve, FDIC, NCUA, and OCC jointly clarified that banks may discuss underlying facts and transactions with customers subject to SARs, provided they do not reveal the SAR's existence.
- PTAB denies patent owner's request over failure to cite own prior art
Patent practitioners should note PTAB's emphasis on patent owners' duty to cite relevant prior art from their own file history when seeking discretionary denial of IPR petitions.
- USCIS Moves to End 60-Day Grace Period; DOL Regulatory Push Continues
OIRA cleared a USCIS proposal to eliminate the 60-day grace period for certain nonimmigrant workers, while House Republicans advanced legislation and DOL rulemaking on contractor status, joint employment, and heat standards.